TY  - JOUR
T1  - Characterization of a Cytotoxic Transglutaminase from Mycobacterium spp. Driving RIPK1 Activation
A1  - Claire Martin
A1  - Julien Robert
A1  - Sophie Bernard
A1  - Antoine Girard
JF  - Bulletin of Pioneering Researches of Medical and Clinical Science
JO  - Bull Pioneer Res Med Clin Sci
SN  - 3006-2659
Y1  - 2024
VL  - 4
IS  - 2
DO  - 10.51847/CGQOBHS5ci
SP  - 167
EP  - 176
N2  - Although worldwide tuberculosis case rates have dropped in the last few years, the disease persists as an immense challenge to global public health. The Mycobacterium tuberculosis complex (MTBC), comprising M. tuberculosis, M. bovis, and M. microti, among others, stands as the most lethal Mycobacterium spp. warranting intensified scrutiny. Research focused on M. microti is particularly important given its status as a zoonotic pathogen capable of moving between animal reservoirs and people. By probing the role of a transglutaminase enzyme in M. microti (MmTG), which is broadly present across Mycobacterium and other organisms, a putative cytotoxic effector has been delineated. MmTG blocks cellular multiplication through the induction of RIPK1 (receptor-interacting serine/threonine-protein kinase 1) phosphorylation, and the Cys159 position of MmTG represents the highly conserved residue tied to its toxic activity. Deciphering MmTG and its homologs can yield a deeper understanding of mycobacterial disease mechanisms and support the design of more efficacious treatment options for mycobacterial infections.
UR  - https://bprmcs.com/article/characterization-of-a-cytotoxic-transglutaminase-from-mycobacterium-spp-driving-ripk1-activation-ubkhwz34c1aajs8
ER  -